US 10167312
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted A61KA61K38/08A61P
Quick answer
US patent 10167312 (Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers) held by RHYTHM PHARMACEUTICALS, INC. expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- RHYTHM PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K38/08, A61P, A61P3/00, A61P3/04